PHAR | Ticker Profile - Titan Protect

PHAR

Pharming Group N.V.

Healthcare · Biotechnology · NGM

$12.54

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$947M

Total market value of the company

Trailing P/E

70.58

Expensive — high growth expected

Forward P/E

46.19

Based on estimated future earnings — lower means cheaper

Rev Growth

-8.4%

Year-over-year revenue change

Profit Margin

3.3%

How much profit the company keeps from each dollar of revenue

ROE

5.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$37.00

+195% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 4 analysts covering this stock

About Pharming Group N.V.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

https://www.pharming.com

Country: Netherlands Employees: 407 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.632

Good returns relative to risk taken

Kelly Fraction

0.0239

Modest edge detected — smaller position warranted

Calmar Ratio

0.495

Drawdown risk outweighs the returns — higher risk profile

Annual Return

21.5%

Historical annualised return based on price data

Max Drawdown

-43.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.12

Very low correlation to market moves

52W High

$21.34

41% below the year high

52W Low

$9.54

32% above the year low

Avg Volume

17,340

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

0.0%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.19

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

43.21

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.63

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.05

Like current ratio but excludes inventory — stricter test

Gross Margin

88.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-6.8%

Profit from core operations before interest and tax

Free Cash Flow

$59M

Positive — the business generates more cash than it spends

Revenue (TTM)

$369M

Total revenue over the last 12 months

Net Income

$12M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$40.00

Target Median

$37.00

Target Low

$23.40

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go